{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"1243","upperLimit":"11019","value":"5150"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"-Blood for pharmacokinetics were drawn prior to infusion, 15 minutes after infusion, 30 minutes after infusion, 45 minutes after infusion, 1 hour after infusion, 2 hours after infusion, 4 hours after infusion, 6 hours after infusions, and 24 hours after infusion","dispersionType":"Full Range","groups":[{"description":"* Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis\n* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.","id":"OG000","title":"Subcutaneous (SC) Treatment Plan - Donor"},{"description":"* Conditioning Regimen\n\n  * Cyclophosphamide 60mg/kg/day on Days -3 and -2\n  * TBI 550cGy on Day -1\n* GVHD prophylaxis\n\n  \\*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100\n* PBSC transplant on Day 0","id":"OG001","title":"Recipients"},{"description":"* Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis\n* Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis\n* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.","id":"OG002","title":"Intravenous (IV) Treatment Plan - Donor"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics were not performed on 2 patients who were considered replacement patients.","reportingStatus":"POSTED","timeFrame":"0 to 24 hours after dose of IV AMD3100","title":"To Determine the Pharmacokinetics of IV AMD3100 (IV Donor Arm Only) as Measured by Mean AUC From Time 0 to Infinity","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}